SLC5A2 and hydrops fetalis: A meta-analysis of SGLT2 inhibitors, involving over 75,000 participants across 31 randomized controlled trials, confirmed consistent reductions in cardiovascular death, HF hospitalizations, and serious AF events, highlighting their efficacy in HFrEF management regardless of AF presence [19].